Or maybe from patients who were on Avonex and Rebif. I don't think there is clarity who these patients really are at this point, too early in launch process. I don't doubt Tecfidera would be a successful MS drug, the question is how successful. Quick launch in MS doesn't mean bigger success longer term, and vice versa.
Market Data 
Markets 
AI
